Supplementary Material

# Supplementary Tables

**Supplemental Table 1: Study schedule and assessments**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Visits assessments** | **Screening/ baseline** | **Post-procedure/ at discharge** | **Follow-up visits** | | | |
| **1-month** | **6-month** | **12-month** | **24-month** |
| **Informed consent** | X |  |  |  |  |  |
| **Inclusion/exclusion criteria** | X |  |  |  |  |  |
| **Demographics** | X |  |  |  |  |  |
| **Medical history** | X |  |  |  |  |  |
| **Physical examination** | X |  |  | X |  |  |
| **Vital signs** | X |  |  | X |  |  |
| **Electrocardiogram (ECG)** | X |  | X\* | X | X\* | X\* |
| **Urine pregnancy test (UPT)** | X |  |  |  |  |  |
| **Laboratory assessment** | X |  | X\*\* | X\*\* | X\*\* | X\*\* |
| **Angiography** | X# |  |  | X\*\*\* |  |  |
| **Percutaneous transluminal coronary angioplasty** | X |  |  |  |  |  |
| **User rating on technical properties** | X |  |  |  |  |  |
| **Current medication including antiplatelet therapy** | X | X | X | X | X | X |
| **AE/SAE/MACE** | X | X | X | X | X | X |
| \*ECG would be optional at 1-month, 1-year and 2-year follow-up, \*\* laboratory assessments would be optional at 1-month, 6-month, 1-year and 2-year follow-up, laboratory assessment will include complete blood count, serum creatinine test, # angiography: angiogram must be captured pre-procedure at baseline as well as post-procedure, \*\*\*30% of the patients will be considered for 6-month angiographic follow-up for late lumen loss analysis based on patients’ consent. For all these patients 6-month visit will be clinical visit. PK sampling and clinical FU will be performed prior to procedure, immediately after deployment within 5 min, at 30 min (± 2 min), 1 hr (± 5 min), 4 hrs (± 5 min), 24hrs (± 10 min), 7 days (± 1 day), and 14 days (± 1 day). | | | | | | |